Did you know that more than 15 million people worldwide are living with a #spinalcordinjury (SCI)? Rehabilitation is a challenging journey that requires resilience, dedication, and comprehensive care, but with the right support, individuals can achieve remarkable levels of independence and quality of life.
Info
At Merz Therapeutics, we seek to address the unique needs of people who suffer from movement disorders, neurological conditions, and other health conditions that severely impact patients’ quality of life. With our patient-centric approach, cutting-edge research and development efforts, highly-scientific medical affairs resources and dedicated commercial teams, we continue the advancement of new and individualized treatment standards, including botulinum toxin. Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that serve unmet patient and customer needs.
- Website
-
https://www.merztherapeutics.com
Externer Link zu Merz Therapeutics
- Branche
- Arzneimittelherstellung
- Größe
- 501–1.000 Beschäftigte
- Hauptsitz
- Frankfurt am Main
- Art
- Privatunternehmen
- Spezialgebiete
- Neurotoxins, Neurology, Neurosciences und Therapeutics
Orte
Beschäftigte von Merz Therapeutics
Updates
-
The innovative strength of our R&D team illustrates the power of collaboration and diversity to achieve breakthroughs in patient care. Together, we are committed to pushing the boundaries of medical science to deliver #BetterOutcomesForMorePatients.
-
For investors and media: We are excited to announce that Merz Therapeutics has officially closed on the acquisition of two commercial medicines, INBRIJA® and AMPYRA®, from Acorda Therapeutics. With these products officially a part of our growing portfolio, we will be able to offer additional treatment options for #Parkinsons related symptoms and, for the first time, #MultipleSclerosis (MS) walking difficulties. The addition of these assets underlines Merz Therapeutics’ global Pivot for Growth strategy to evolve both the current portfolio and achieve critical scale and global reach through acquisitions, while delivering on our ongoing commitment of bringing #BetterOutcomesForMorePatients. Merz Therapeutics is poised to continue building on what we have accomplished in the specialty neurology space by strengthening our market position in Parkinson’s disease and entering the MS segment. This deal demonstrates the organization’s interest and ability to acquire assets in neurology-focused specialty care, driven by the needs of people living with movement disorders and neurological conditions. Read more about the acquisition in our press release: https://lnkd.in/g6yQHSNr #HealthcareInnovation #NeurologyCare Important Safety information: https://lnkd.in/gKbduB4q https://lnkd.in/gyZrZZdr European Medicines Agency (EMA): https://lnkd.in/ezxdVzSP https://lnkd.in/e7g2QT2d
-
Did you know that 75% to 80% of people living with #cerebralpalsy experience spasticity? This symptom can lead to a limited range of joint motion, reduced motor function, and pain. By addressing these challenges and showing our support, we can help individuals lead more independent and fulfilling lives. Let’s work together to build a more inclusive and supportive community. #BetterOutcomesForMorePatients
-
As we continue to push the boundaries of innovation in the pharmaceutical industry, the role of patient advocacy organizations in R&D has never been more important. Patient organizations bring invaluable perspectives that help shape clinical development programs, making them more effective and patient-centered. At #MerzTx, we're proud to put patients first: Their voices are not only heard, but they are also integral to our work, from the early stages of research to the final stages of development. Learn more about the patient organizations we work with: https://lnkd.in/dY48tpz7
-
Ensuring continued safety of our products is vital to our mission: Better outcomes for more patients. Julia Pfaff, our Head of Pharmacovigilance, sheds light on the critical process of post-approval product monitoring. Explore our clinical breakthroughs: https://lnkd.in/eT_aduCR
-
Understanding #dystonia can be challenging, as the complex neurological disorder is not widely known. Educating ourselves and others about neurological disorders like dystonia can lead to better support systems and treatment approaches for those affected. Learn more: https://lnkd.in/e-nwzn4m
-
In this interview, Dr. Rajiv Reebye discusses the role of collaboration between rehabilitation specialists, neurosurgeons, and orthopedic surgeons in spasticity treatment. Early teamwork, beginning in residency, can set the stage for better outcomes and prepare medical professionals to effectively manage complex cases.
-
It's hard to believe that it's already been a year since we opened our #MerzTx Nordics affiliate. In that time, we've welcomed talented individuals from Denmark, Norway, and Sweden to our team, and together we've achieved remarkable milestones. We're immensely grateful to each colleague for their unwavering commitment to delivering #BetterOutcomesForMorePatients. Here's to continued success and growth in the journey ahead!
-
We were delighted to welcome our partner Teijin Limited to our headquarters in Frankfurt, Germany. Throughout our eight-year partnership, we have been able to bring #BetterOutcomesForMorePatients to Japan and address critical unmet needs in spasticity and stroke rehabilitation. Learn more about our partnerships at Merz Therapeutics: https://lnkd.in/ezBCgQNr